Literature DB >> 3128489

Inflammatory cell infiltrates in human melanoma at different stages of tumor progression.

E B Bröcker1, G Zwadlo, B Holzmann, E Macher, C Sorg.   

Abstract

Progression of human melanoma is associated with changes in antigenic phenotypes of tumor cells. To establish whether inflammatory infiltrates in progressing melanoma also change, we studied 146 cutaneous melanomas at different stages of progression. Monoclonal antibodies (MAbs) against lymphocyte and macrophage subpopulations, interleukin-2 receptor (IL-2 R), immune interferon (IFN-gamma), and the IFN-gamma-inducible, progression-associated melanoma antigens HLA-DR and gp89 were applied in situ. During the course of melanoma progression, decreased amounts of peritumoral T cells, IL-2 R-expressing lymphocytes and dermal T6+ dendritic cells were found, while increased numbers of intratumoral T cells, inflammatory (27E10+) and mature (25F9+) macrophages were associated with local progression of primary melanomas. In metastases, most infiltrate components except 25F9+ macrophages were rare. Positive correlations were observed between: (1) dermal T6+ cells and IL-2 R+ lymphocytes, and (2) presence of IFN-gamma in the infiltrate and HLA-DR and gp89 antigens on tumor cells. In all stages, HLA-DR expression on tumor cells was correlated with: (1) a shift towards T8+ lymphocytes in the infiltrates and (2) a loss of IL-2 R expression. Our data suggest mutual influences between melanoma cells and mononuclear cell infiltrates in situ.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128489     DOI: 10.1002/ijc.2910410415

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

1.  Breast Cancer: A Revolutionary Concept.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

Review 2.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 3.  Photoimmunology of experimental melanoma.

Authors:  C K Donawho; M L Kripke
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 4.  Melanoma vaccines. Current status and future prospects.

Authors:  P Hersey
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

5.  Immunohistochemical analysis of markers for different macrophage phenotypes and their use for a forensic wound age estimation.

Authors:  P Betz; J Tübel; W Eisenmenger
Journal:  Int J Legal Med       Date:  1995       Impact factor: 2.686

6.  Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Authors:  Paige M Kulling; Kristine C Olson; Thomas L Olson; Cait E Hamele; Kathryn N Carter; David J Feith; Thomas P Loughran
Journal:  J Steroid Biochem Mol Biol       Date:  2017-07-20       Impact factor: 4.292

7.  T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.

Authors:  Q Chen; M Smith; T Nguyen; D W Maher; P Hersey
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

8.  Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.

Authors:  Y Tomita; H Watanabe; H Kobayashi; T Nishiyama; S Tsuji; M Fujiwara; S Sato
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes.

Authors:  C J Punt; J A Barbuto; H Zhang; W J Grimes; K D Hatch; E M Hersh
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

10.  On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Authors:  M R Bernsen; L Håkansson; B Gustafsson; L Krysander; B Rettrup; D Ruiter; A Håkansson
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.